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According to the World Health Organization (WHO), cardiovascular diseases 
(CVD) represented about 31 % of all mortalities in the world and affected about 18 million 
persons around the world in 2015. Venous thrombosis including deep vein thrombosis 
(DVT) and pulmonary embolism (PE) is considered the third most common cardiovascular 
disease in the western population following coronary artery disease and stroke with esti-
mated incidence of 1 per 1000 persons per year. Rates increase with age to 1 per 100 persons 
in elderly people over 75 years old [1]. Venous thrombosis is a threatening disease with 
major outcomes of death, post-thrombotic syndrome and recurrence and bleeding compli-
cations due to use of anticoagulant therapy. For the prevention and treatment of cardiovas-
cular disease, clinical and applied research has to be conducted in parallel with fundamental 
research in order to provide the basic knowledge which is needed to find diagnostic and 
therapeutic solutions and eventually lead to improvements in health care and quality of life 
thereby serving a major societal need. 
             Currently available antithrombotic treatments increase the bleeding risk in some 
patients. Therefore, more scientific research and more studies are needed to investigate and 
understand the biological mechanisms related to blood coagulation in order to find effective 
diagnostic and therapeutic solutions for patients with venous thrombosis. 
 The connection between curiosity-driven and translational research is of key value 
to this PhD project. The content of this thesis provides insight into the natural anticoagulant 
properties of protein S and its biological variants as a result of basic research. In addition, 
as a result of applied research, in this thesis new functional assays are presented for the 
measurement of protein S activity in plasma which can be used as a reliable tool for the 
diagnosis of protein S deficiency.  
 Protein S activity assays used in the diagnosis of protein S deficiency are based on 
measuring APC cofactor activity of protein S, and in a recent study [2] it was shown that 
the FV Leiden mutation and anticoagulant medication can interfere with the outcome of 
these assays. Therefore, we used calibrated automated thrombography to develop new func-
tional assays that enable selective quantification of both the APC and TFPI cofactor activi-
ties of protein S in plasma which are not affected by the presence of the FV Leiden mutation. 
The assays yielded reliable quantification of protein S activity and could discriminate be-
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tween protein S deficient plasma samples and plasma samples with normal protein S activ-
ity. The assays also reliably perform when applied to various types of acquired protein S 
deficiency. Although our assay is currently only available as a research tool, optimization 
and simplification of the assay could lead to a novel commercial assay that could replace 
the current functional protein S assays. 
 In the present thesis we also investigated regulation of protein S activity by prote-
olysis and binding to C4BP and showed that cleaved protein S retains full TFPI cofactor 
activity but is not active as cofactor of APC and that C4BP-bound protein S is partly active 
both as APC and as TFPI cofactor.  
 In addition, we showed that protein S-dependent down-regulation of thrombin gen-
eration at low as well as high TF is greatly dependent on plasma concentrations of APC and 
TFPI. Since protein S deficiency is associated with a decreased plasma level of TFPI [3], 
these findings suggest that the thrombosis risk of protein S-deficient patients is amplified 
by the low TFPI plasma levels.  
 In all, these findings are valuable additions to our basic knowledge about biologi-
cal activity of protein S variants and could aid in further unraveling of the mechanistic 
properties of protein S leading to a better understanding and prevention of thrombotic 
disease.  
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